NCT00872651

Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 242 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Eligible patients will be randomized in a 1.1 ratio to receive Travoprost 0.004%/timolol 0.5% once daily or Latanoprost 0.005%/Timolol 0.5% once a day for 8 Weeks. The study treatments will be compared for mean diurnal intraocular pressure (IOP) change from baseline at Week 8. Safety parameters measured at 4 study visits: ocular signs, visual acuity, dilated fundus, cardiovascular parameters (blood pressure and pulse), and adverse events.

Conditions

• Open-angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Travoprost 0.004%/Timolol 0.5%	Travoprost 0.004%/Timolol 0.5%
DRUG	Latanoprost 0.005% / Timolol 0.5%	Latanoprost 0.005% / Timolol 0.5%

Timeline

• Start date: 2010-01-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2009-03-31
• Last updated: 2013-03-28

Locations

1 site across 1 country: China